Dissecting Pathogenetic Mechanisms and Therapeutic Strategies in Drosophila Models of Myotonic Dystrophy Type 1

Int J Mol Sci. 2018 Dec 18;19(12):4104. doi: 10.3390/ijms19124104.

Abstract

Myotonic dystrophy type 1 (DM1), the most common cause of adult-onset muscular dystrophy, is autosomal dominant, multisystemic disease with characteristic symptoms including myotonia, heart defects, cataracts and testicular atrophy. DM1 disease is being successfully modelled in Drosophila allowing to identify and validate new pathogenic mechanisms and potential therapeutic strategies. Here we provide an overview of insights gained from fruit fly DM1 models, either: (i) fundamental with particular focus on newly identified gene deregulations and their link with DM1 symptoms; or (ii) applied via genetic modifiers and drug screens to identify promising therapeutic targets.

Keywords: DM1; Drosophila; animal model; drug screen; genetic screen; muscular dystrophy; therapeutic targets.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Drosophila melanogaster / genetics
  • Drug Evaluation, Preclinical
  • Humans
  • Molecular Targeted Therapy
  • Muscle, Skeletal / physiopathology*
  • Myotonic Dystrophy / genetics*
  • Myotonic Dystrophy / pathology
  • Myotonic Dystrophy / therapy*
  • Myotonin-Protein Kinase / antagonists & inhibitors
  • Myotonin-Protein Kinase / genetics*
  • Trinucleotide Repeat Expansion / genetics

Substances

  • Myotonin-Protein Kinase

Grants and funding